Imbed Biosciences Inc. is a privately held medical device company and innovator of SAMatrix™ Technology, with both commercially available and emerging pipeline solutions.
Imbed is changing the paradigm of wound care with its revolutionary SAMatrix™ platform technology that integrates multiple wound care agents into an ultra-thin, fully synthetic matrix composed of bioresorbable fibers. SAMatrix™ is designed to help protect wounds and facilitate wound healing.
Imbed’s current SAMatrix™ portfolio includes Surgaflex®, Pelashield®, and Microlyte®, with antimicrobial silver integrated into the matrix. The portfolio now also includes Microlyte® PainGuard®, Pelashield® PainGuard®, and Surgaflex® PainGuard®, with the addition of lidocaine HCl to manage pain along with bioburden reduction. These brands are indicated across a wide range of chronic and acute wounds, including ulcers, surgical, traumatic, and burn wounds.
Imbed Biosciences is registered with the U.S. FDA as a medical device manufacturer and maintains an ISO 13485:2016 certified Quality Management System.
Study Registration (NCT07695688) Supports Imbed’s Ongoing Effort to Address Biofilm — a Persistent Challenge Across Wound Care and Beyond MIDDLETON, Wis., Oct. 1, 2026 /PRNewswire/ — Imbed Biosciences, developer of
Mark your calendar for October 22–23 and join us for the Midwest Regional Burn Conference at The Ohio State University Wexner Medical Center in Columbus, Ohio. More than just a